Condition: Hepatitis B · Sponsor: GC Biopharma Corp
The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients
This description comes directly from the study's public registry record.
Jiyoung Sin · 82-(0)31-260-9570 · jiyoung.sin@gccorp.com
Always discuss trial participation with your own doctor first.
| National Cancer Center | Goyang-si, Gyeonggi-do, South Korea | Recruiting |
| Ajou University Medical Center | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Asan Medical Center | Seoul, Seoul, South Korea | Recruiting |
| Inje University Haeundae Paik Hospital | Busan, South Korea | Recruiting |
| Chungnam National University Hospital | Daejeon, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05686759